2008
A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluorouracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases
Fu S, Chintala L, Madoff D, Hong D, Naing A, Moulder S, Wheler J, Ng C, Lim J, Patterson M, Kurzrock R. A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluorouracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases. Journal Of Clinical Oncology 2008, 26: 2534-2534. DOI: 10.1200/jco.2008.26.15_suppl.2534.Peer-Reviewed Original Research
1996
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. Journal Of Clinical Oncology 1996, 14: 1818-28. PMID: 8656250, DOI: 10.1200/jco.1996.14.6.1818.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyDoxorubicinFemaleFluorouracilHumansInfusions, IntravenousInfusions, ParenteralMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalRisk FactorsStomach NeoplasmsSurvival RateUltrasonographyConceptsMedian survival durationCurative resectionOperative morbiditySurvival durationEndoscopic ultrasonographyGastric cancerLocally advanced gastric cancerMedian follow-up timePostoperative IP chemotherapyTreatment-related deathsPhase II trialAdvanced gastric cancerFollow-up timeFAMTX regimenIntravenous fluorouracilPlanned laparotomyNeutropenic feverPreoperative therapyNeoadjuvant therapyResected patientsIP chemotherapyIP therapyPeritoneal failureEighty-nine percentPathologic tumor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply